Walleye Capital
AMLX icon

Walleye Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Walleye Capital’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.35M Buy
186,588
+124,877
+202% +$1.93M 0.01% 1094
2026
Q1 		$858K Buy
61,711
+55,971
+975% +$787K ﹤0.01% 2218
2025
Q4 		$69.3K Buy
+5,740
New +$78K ﹤0.01% 3994
2025
Q2 		– Sell
-250,888
Closed -$888K – 4459
2025
Q1 		$888K Sell
250,888
-267,896
-52% -$953K ﹤0.01% 2070
2024
Q4 		$1.96M Sell
518,784
-151,810
-23% -$714K ﹤0.01% 1798
2024
Q3 		$2.17M Buy
670,594
+608,874
+987% +$1.37M ﹤0.01% 1865
2024
Q2 		$117K Sell
61,720
-300,150
-83% -$582K ﹤0.01% 4639
2024
Q1 		$1.03M Sell
361,870
-220,858
-38% -$2.89M ﹤0.01% 2563
2023
Q4 		$8.58M Buy
582,728
+481,769
+477% +$7.38M 0.02% 753
2023
Q3 		$1.85M Buy
100,959
+48,581
+93% +$1.03M ﹤0.01% 1800
2023
Q2 		$1.13M Buy
+52,378
New +$1.41M ﹤0.01% 1751
2023
Q1 		– Sell
-17,492
Closed -$646K – 3897
2022
Q4 		$646K Sell
17,492
-44,390
-72% -$1.58M 0.01% 1293
2022
Q3 		$1.74M Buy
+61,882
New +$1.54M 0.03% 638
2022
Q2 		– Sell
-28,187
Closed -$362K – 2322
2022
Q1 		$362K Buy
+28,187
New +$637K 0.01% 1196

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Walleye Capital's AMLX Position: Q2 2026 in Review

Walleye Capital increased its Amylyx Pharmaceuticals (AMLX) stake by 202% in Q2 2026, buying an estimated $1.93M and bringing the position to 186,588 shares worth $3.35M. The position accounts for 0.01% of the portfolio, ranked #1094.

Walleye Capital first reported a position in AMLX in Q1 2022 and has held it in 14 quarters since. The position peaked at $8.58M in Q4 2023. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Walleye Capital held 186,588 shares of Amylyx Pharmaceuticals worth $3.35M as of Q2 2026.
  • Walleye Capital bought 124,877 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $1.93M.
  • Amylyx Pharmaceuticals made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1094 holding.
  • Walleye Capital first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
  • Walleye Capital's Amylyx Pharmaceuticals position peaked at $8.58M in Q4 2023.
  • 207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.